

**Minutes of the September 14, 2012
Pharmacy & Therapeutics (P&T) Committee Meeting
SD Department of Social Services, Medical Services Division**

Members present

Debra Farver, PharmD; Timothy Soundy, MD; Bill Ladwig, RPh; Michelle Baack, MD; Mikel Holland, MD; Kelly Oehlke, PharmD; Lenny Petrick, PharmD

Members absent

Dana Darger, RPh; James Engelbrecht, MD; Rick Holm, MD

DSS staff present

Mike Jockheck, RPh
Ann Schwartz, Dep. Director, Medical Services

HID staff present

Candace Rieth, PharmD

Administrative Business

The P&T meeting was called to order by M. Baack at approximately 1:00pm. The minutes of the June 22, 2012 meeting were presented. D. Farver made a motion to approve. B. Ladwig seconded the motion. The motion was approved unanimously.

Prior Authorization Update and Statistics

C. Rieth presented an overview of the prior authorization (PA) activity for July 2012. There were a total of 2,056 PAs processed in the month of July, with 98.69% of those requests responded to in less than 8 hours. There were 1,701 (83%) requests received electronically and 355 (17%) requests received by fax.

Analysis of the Top 15 Therapeutic Classes

C. Rieth reviewed the Top 15 Therapeutic Classes by total cost of claims from 04/01/2012 – 06/30/2012. The top five classes were antipsychotics, cerebral stimulants, amphetamines, leukotriene modifiers, and corticosteroids (respiratory tract). The top 15 therapeutic classes make up 39.68% of total claims. C. Rieth also reviewed the top 25 drugs based on total claims cost and number of claims. The top 25 drugs by claims cost make up 12.46% of total claims.

Antipsychotics Update

M. Jockheck gave an update on the antipsychotics PA. The class PA will go into effect on October 1st. HID is in the final stages of building the electronic criteria, defining the medications that will require a PA and developing a list of psychiatrists and mid-level practitioners. Another update will be given at the March meeting.

Lidoderm Review

C. Rieth reviewed the prior authorization form and criteria for Lidoderm. T. Soundy made a motion to approve the Lidoderm form and criteria. D. Farver seconded the motion. There was no public comment. The motion was approved unanimously.

Early Refill Review

M. Jockheck reviewed early refill information with the committee. There was no public comment. T. Soundy made a motion to change the early refill percentage from 70% to 76.6%. B. Ladwig seconded the motion. The motion was approved unanimously.

Onfi Review

C. Rieth reviewed the Onfi prior authorization form and criteria. There was no public comment. B. Ladwig made a motion to approve the form and criteria. T. Soundy seconded the motion. The motion was approved unanimously.

Inhaled Corticosteroid Review

C. Rieth reviewed inhaled corticosteroid clinical information and utilization. This topic was tabled for a future meeting.

Nasal Steroids for Allergic Rhinitis Review

C. Rieth reviewed nasal steroid clinical information and utilization. Larry McDermott, representing Sunovion, spoke regarding Zetonna. Sean Carlson, representing Merck, spoke regarding Nasonex. After discussion, B. Ladwig made a motion to establish a PA on nasal steroids for allergic rhinitis. D. Farver seconded the motion. The motion was approved unanimously. A form and criteria will be brought back to the December meeting.

Ophthalmic Prostaglandin Agonists Review

C. Rieth reviewed ophthalmic prostaglandin agonist clinical information and utilization. This topic was tabled for an ophthalmologist consult.

Antiretroviral Review

C. Rieth reviewed utilization information for the antiretrovirals. This topic was tabled until December with a request for trend reports and specific DUR criteria for these medications.

Genitourinary Smooth Muscle Relaxants Review

C. Rieth reviewed genitourinary smooth muscle relaxant clinical information and utilization. This topic was tabled until December with a request for the age distribution of recipients and their indications.

The next meeting date is scheduled for December 14, 2012. A motion was made by D. Farver at 2:00pm to adjourn the SD Medicaid P&T meeting. K. Oehlke seconded the motion. Motion passed unanimously and the meeting was adjourned.